» Articles » PMID: 35634510

Serum Cystatin C Trajectory Is a Marker Associated With Diabetic Kidney Disease

Overview
Specialty Endocrinology
Date 2022 May 31
PMID 35634510
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To explore the association of the trajectory of serum Cystatin C (Cysc) with diabetic kidney disease (DKD), a retrospective cohort study of Chinese subjects was carried out.

Method: A review of 2,928 diabetes mellitus (DM) patients admitted to the clinic and ward of the Endocrinology Department, Shengjing Hospital of China Medical University from January 1, 2014 to December 31, 2014 was performed. Subsequent visits to the hospital were followed until December 31, 2020. The primary endpoint was the incidence of DKD as diagnosed by urinary albumin/creatinine ratio ≥30 mg/g and/or estimated glomerular filtration rate <60 ml/min per 1.73 m. Healthy control subjects were identified from a health checkup database in Shengjing Hospital from 2016 to 2019. The latent class growth mixed modeling (LCGMM) method was used to analyze latent classes of serum Cysc in healthy and DM subjects. Finally, the hazard ratios (HRs) of latent classes of Cysc in DM subjects were analyzed by Cox regression analysis.

Results: A total of 805 type 2 diabetes mellitus (T2DM) and 349 healthy subjects were included in the trial. The HRs of quartiles of baseline Cysc in T2DM subjects were 7.15 [95% confidence interval (CI), 2.79 to 25.57], 2.30 (95% CI, 1.25 to 4.24), and 2.05 (95% CI, 1.14 to 3.70), respectively, for quartile 4 (Q4), Q3, and Q2 when compared with Q1. Through LCGMM, a 1-class linear model was selected for the Cysc latent class in healthy subjects. In contrast, a 3-class linear model was selected for that in DM subjects. The slopes of the three latent classes in T2DM subjects were larger than the slope in healthy subjects. The HRs of incident DKD were 3.43 (95% CI, 1.93 to 6.11) for the high-increasing class and 1.80 (95% CI, 1.17 to 2.77) for the middle-increasing class after adjusting for confounding variables.

Conclusions: Patients with T2DM had a higher velocity of increase in Cysc than healthy subjects. Patients with high baseline Cysc values and high latent increasing velocity of Cysc had a higher risk of developing DKD in later life. More attention should be paid to patients with these high-risk factors.

Citing Articles

Augmented Intrarenal and Urinary Angiotensinogen in Diabetic Nephropathy: The Role of Isoflavones.

Kamiyama M, Iijima K, Okuzawa R, Kawata R, Kimura A, Shinohara Y Int J Mol Sci. 2025; 26(4).

PMID: 40003909 PMC: 11855285. DOI: 10.3390/ijms26041443.


Cystatin C to Left Ventricular Ejection Fraction Ratio as a Novel Predictor of Adverse Outcomes in Patients with Coronary Artery Disease: A Prospective Cohort Study.

Ning Y, Wang K, Min X, Hou X, Wu T, Ma Y Rev Cardiovasc Med. 2024; 24(9):260.

PMID: 39076386 PMC: 11270069. DOI: 10.31083/j.rcm2409260.


Multiomics Analyses Identify AKR1A1 as a Biomarker for Diabetic Kidney Disease.

Li D, Hsu F, Palmer N, Liu L, Choi Y, Murea M Diabetes. 2024; 73(7):1188-1195.

PMID: 38394643 PMC: 11189831. DOI: 10.2337/db23-0540.


Measurement of renal function: Should cystatin C be more widely used for people with diabetes?.

Mende C, Bloomgarden Z J Diabetes. 2024; 16(1):e13534.

PMID: 38282206 PMC: 10822779. DOI: 10.1111/1753-0407.13534.


Expression of TNFR1, VEGFA, CD147 and MCT1 as early biomarkers of diabetes complications and the impact of aging on this profile.

Raimundo J, Alves B, Encinas J, Siqueira A, de Gois K, Perez M Sci Rep. 2023; 13(1):17927.

PMID: 37863950 PMC: 10589356. DOI: 10.1038/s41598-023-41061-0.


References
1.
Norlund L, Fex G, Lanke J, von Schenck H, Nilsson J, Leksell H . Reference intervals for the glomerular filtration rate and cell-proliferation markers: serum cystatin C and serum beta 2-microglobulin/cystatin C-ratio. Scand J Clin Lab Invest. 1997; 57(6):463-70. DOI: 10.3109/00365519709084595. View

2.
Miao Y, Ottenbros S, Laverman G, Brenner B, Cooper M, Parving H . Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension. 2011; 58(1):2-7. DOI: 10.1161/HYPERTENSIONAHA.111.171488. View

3.
Finney H, Newman D, Price C . Adult reference ranges for serum cystatin C, creatinine and predicted creatinine clearance. Ann Clin Biochem. 2000; 37 ( Pt 1):49-59. DOI: 10.1258/0004563001901524. View

4.
Tuttle K, Bakris G, Bilous R, Chiang J, de Boer I, Goldstein-Fuchs J . Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care. 2014; 37(10):2864-83. PMC: 4170131. DOI: 10.2337/dc14-1296. View

5.
Abrahamson M, Olafsson I, Palsdottir A, Ulvsback M, Lundwall A, Jensson O . Structure and expression of the human cystatin C gene. Biochem J. 1990; 268(2):287-94. PMC: 1131430. DOI: 10.1042/bj2680287. View